Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.

Malignant Pleural Effusion Market Expected To Reach $6.51 Billion By 2030 At 6.6% CAGR

The malignant pleural effusion sector experienced robust expansion lately. Projections indicate a rise from $4.73 billion in 2025 to $5.05 billion in 2026, reflecting a compound annual growth rate of 6.8%. Historical expansion drivers included a greater occurrence of metastatic cancers, a scarcity of treatment methodologies offering cures, the necessity for frequent thoracentesis to alleviate symptoms, the expansion of inpatient cancer treatment facilities, and the progressive acceptance of pleurodesis procedures.

The market for malignant pleural effusion is poised for substantial expansion over the coming years, projected to reach $6.52 billion by 2030, reflecting a compound annual growth rate of 6.6%. This anticipated growth trajectory is fueled by an increasing incidence of cancer globally, coupled with ongoing innovations in pleural catheter technology, a discernible shift towards outpatient and home-care models, enhanced precision in diagnostic imaging techniques, and a heightened demand for therapeutic interventions prioritizing patient quality of life. Key developments anticipated within this period involve a greater adoption of indwelling pleural catheters for sustained management, a trend favoring less invasive procedures for pleural conditions, the increasing incorporation of systemic cancer treatments into MPE management strategies, a stronger emphasis on relief of symptoms and palliative care, and the broader application of imaging-guided methods for both diagnosis and treatment.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=22047&type=smp

Malignant Pleural Effusion Market Growth Factors Supporting Long-Term Expansion

An escalation in lung cancer diagnoses is anticipated to fuel the expansion of the malignant pleural effusion market. Lung cancer, defined by the uncontrolled proliferation of aberrant cells within the lungs, can manifest as tumors that disrupt normal pulmonary function. Factors such as smoking and tobacco consumption are primary contributors to the increasing incidence of lung cancer, as extended exposure to cigarette constituents inflicts damage on lung tissues, instigates genetic alterations, and fosters the unrestrained growth of malignant cells, thereby substantially elevating the risk of developing the ailment. Malignant pleural effusion signifies a more advanced stage of lung cancer, characterized by the dissemination of the tumor into the pleural space, leading to compromised respiratory capacity and a less favorable prognosis. Illustratively, the American Cancer Society Facts and Figures reported that in the United States, estimated new cases of lung and bronchus cancer were 236,740 in 2022 and projected to be 238,340 in 2023, with corresponding death estimates of 130,180 in 2022 and 127,070 in 2023. Consequently, the growing prevalence of lung cancer is directly stimulating the growth of the malignant pleural effusion market.

Advances in healthcare infrastructure are poised to catalyze the expansion of the malignant pleural effusion market. This infrastructure encompasses the physical, technological, and organizational frameworks essential for healthcare delivery, including medical facilities, sophisticated equipment, robust IT systems, and skilled personnel. Such improvements are driven by the imperative for more effective disease management, collectively enhancing accessibility to healthcare, operational efficiency, and the overall caliber of medical services. By providing access to cutting-edge medical technologies, well-resourced healthcare settings, and specialized medical expertise, enhanced healthcare infrastructure facilitates more accurate diagnosis, effective treatment, and proficient management of malignant pleural effusion, ultimately leading to improved patient health outcomes. As an illustration, the American Health Care Association noted a rise in the number of hospitals across the United States, increasing by 0.591% from 6,093 to 6,129 between May 2022 and May 2023. Therefore, the ongoing enhancements in healthcare infrastructure are acting as a key driver for the growth observed in the malignant pleural effusion market.

Malignant Pleural Effusion Market Segmentation And Category Breakdown

The malignant pleural effusion market covered in this report is segmented –

1) By Treatment: Systemic Therapy, Therapeutic Thoracentesis, Thoracic Drainage And Pleurodesis, Indwelling Pleural Catheter

2) By Diagnosis: Pleural Fluid Cytology, Immunohistochemical Tests, Imaging Tests, Pleural Thoracentosis, Pleuroscopy, Pleural Biopsy

3) By End Users: Hospitals, Ambulatory Clinics, Other End Users

Subsegments:

1) By Systemic Therapy: Chemotherapy, Targeted Therapy, Immunotherapy

2) By Therapeutic Thoracentesis: Single-Time Thoracentesis, Repeated Thoracentesis

3) By Thoracic Drainage And Pleurodesis: Chemical Pleurodesis, Mechanical Pleurodesis

4) By Indwelling Pleural Catheter: Tunneled Pleural Catheter, Non-Tunneled Pleural Catheter

Malignant Pleural Effusion Market Industry Trends Shaping Future Revenue Growth

In the realm of the malignant pleural effusion market, leading enterprises are concentrating their efforts on pioneering novel solutions, exemplified by the creation of fully implantable automatic fluid-shunt devices, aiming to enhance patient well-being and decrease the frequency of hospitalizations. These sophisticated medical devices, once surgically placed within the body, possess the capability to autonomously evacuate surplus pleural fluid from the lungs into the abdominal cavity or an alternative location, thereby alleviating symptoms such as shortness of breath, diminishing the necessity for repeated medical interventions, and ultimately elevating the patient’s overall quality of life. A notable illustration of this advancement is the introduction of the ACES Automatic Continuous Effusion Shunt System by Pleural Dynamics, a medical device firm based in the United States, in October of 2023. This ingenious system incorporates a flexible, durable pump chamber designed for subcutaneous implantation between the patient’s ribs, connected by catheters to both the pleural space and the peritoneal space. The patient’s natural breathing motion alternately compresses and expands the internal pump extension situated between the ribs, propelling fluid from the pleural cavity into the abdomen for natural reabsorption; furthermore, the system includes an external compression extension that permits manual activation when needed. The primary advantages of this innovative technology encompass its completely internal placement, dispensing with external drainage apparatus or collection containers, its automatic fluid transfer mechanism powered by the patient’s respiration, a brief hospital stay requirement for the implantation procedure, and the provision of persistent relief from the discomfort associated with recurring effusions.

Malignant Pleural Effusion Market Competitive Analysis Of Major Industry Participants

Major companies operating in the malignant pleural effusion market are Becton Dickinson and Company, Cook Medical LLC, Merit Medical Systems Inc, Argon Medical Devices Inc, B Braun SE, Medtronic plc, Smiths Medical, Teleflex Incorporated, Cardinal Health Inc, Getinge AB, AngioDynamics Inc, Rocket Medical plc, Redax SpA, Atrium Medical Corporation, PolyMedicure Ltd, Troge Medical GmbH, Vygon SA, ICU Medical Inc, ConvaTec Group plc, Baxter International Inc

Access The Complete Malignant Pleural Effusion Market Report:

https://www.thebusinessresearchcompany.com/report/malignant-pleural-effusion-global-market-report

Malignant Pleural Effusion Market Geographic Distribution And Regional Opportunities

North Americawas the largest region in the malignant pleural effusion market in 2025. Asia-Pacificis expected to be the fastest-growing region in the forecast period. The regions covered in the malignant pleural effusion market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model